Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 13, 2021

SELL
$170.47 - $211.93 $8.62 Million - $10.7 Million
-50,595 Closed
0 $0
Q1 2021

May 14, 2021

SELL
$153.94 - $174.85 $7.21 Million - $8.19 Million
-46,868 Reduced 48.09%
50,595 $8.46 Million
Q4 2020

Feb 16, 2021

BUY
$101.87 - $151.79 $4.19 Million - $6.24 Million
41,123 Added 72.99%
97,463 $14.8 Million
Q3 2020

Nov 04, 2020

SELL
$99.9 - $121.13 $2.35 Million - $2.85 Million
-23,508 Reduced 29.44%
56,340 $5.69 Million
Q2 2020

Jul 31, 2020

SELL
$92.74 - $125.82 $993,523 - $1.35 Million
-10,713 Reduced 11.83%
79,848 $9.66 Million
Q1 2020

May 08, 2020

SELL
$79.39 - $115.35 $2.56 Million - $3.72 Million
-32,215 Reduced 26.24%
90,561 $8.59 Million
Q4 2019

Feb 11, 2020

BUY
$78.31 - $95.34 $4.4 Million - $5.35 Million
56,137 Added 84.24%
122,776 $10.8 Million
Q3 2019

Nov 01, 2019

BUY
$74.85 - $85.99 $2.01 Million - $2.31 Million
26,915 Added 67.76%
66,639 $5.31 Million
Q2 2019

Aug 13, 2019

SELL
$76.06 - $120.81 $1.24 Million - $1.97 Million
-16,279 Reduced 29.07%
39,724 $3.1 Million
Q1 2019

May 13, 2019

BUY
$107.15 - $126.84 $619,648 - $733,515
5,783 Added 11.52%
56,003 $6.57 Million
Q4 2018

Feb 14, 2019

SELL
$101.4 - $128.73 $2.71 Million - $3.44 Million
-26,693 Reduced 34.71%
50,220 $5.47 Million
Q3 2018

Nov 14, 2018

BUY
$113.81 - $129.46 $6.88 Million - $7.83 Million
60,451 Added 367.22%
76,913 $9.84 Million
Q2 2018

Aug 06, 2018

SELL
$101.14 - $118.31 $11.1 Million - $13 Million
-109,912 Reduced 86.97%
16,462 $1.86 Million
Q1 2018

May 03, 2018

BUY
$107.21 - $151.94 $13.5 Million - $19.2 Million
126,374 New
126,374 $14.2 Million

Others Institutions Holding UTHR

About UNITED THERAPEUTICS Corp


  • Ticker UTHR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,516,300
  • Market Cap $15.8B
  • Description
  • United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertensio...
More about UTHR
Track This Portfolio

Track Mackay Shields LLC Portfolio

Follow Mackay Shields LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

News

Stay updated on Mackay Shields LLC with notifications on news.